↓ Skip to main content

Dove Medical Press

Cell-based therapies of liver diseases: age-related challenges

Overview of attention for article published in Clinical Interventions in Aging, December 2015
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age
  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 X users
facebook
1 Facebook page

Citations

dimensions_citation
14 Dimensions

Readers on

mendeley
40 Mendeley
Title
Cell-based therapies of liver diseases: age-related challenges
Published in
Clinical Interventions in Aging, December 2015
DOI 10.2147/cia.s97926
Pubmed ID
Authors

Konstantin N Yarygin, Alexei Y Lupatov, Irina V Kholodenko

Abstract

The scope of this review is to revise recent advances of the cell-based therapies of liver diseases with an emphasis on cell donor's and patient's age. Regenerative medicine with cell-based technologies as its integral part is focused on the structural and functional restoration of tissues impaired by sickness or aging. Unlike drug-based medicine directed primarily at alleviation of symptoms, regenerative medicine offers a more holistic approach to disease and senescence management aimed to achieve restoration of homeostasis. Hepatocyte transplantation and organ engineering are very probable forthcoming options of liver disease treatment in people of different ages and vigorous research and technological innovations in this area are in progress. Accordingly, availability of sufficient amounts of functional human hepatocytes is crucial. Direct isolation of autologous hepatocytes from liver biopsy is problematic due to related discomfort and difficulties with further expansion of cells, particularly those derived from aging people. Allogeneic primary human hepatocytes meeting quality standards are also in short supply. Alternatively, autologous hepatocytes can be produced by reprogramming of differentiated cells through the stage of induced pluripotent stem cells. In addition, fibroblasts and mesenchymal stromal cells can be directly induced to undergo advanced stage hepatogenic differentiation. Reprogramming of cells derived from elderly people is accompanied by the reversal of age-associated changes at the cellular level manifesting itself by telomere elongation and the U-turn of DNA methylation. Cell reprogramming can provide high quality rejuvenated hepatocytes for cell therapy and liver tissue engineering. Further technological advancements and establishment of national and global registries of induced pluripotent stem cell lines homozygous for HLA haplotypes can allow industry-style production of livers for immunosuppression-free transplantation.

X Demographics

X Demographics

The data shown below were collected from the profiles of 3 X users who shared this research output. Click here to find out more about how the information was compiled.
Mendeley readers

Mendeley readers

The data shown below were compiled from readership statistics for 40 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Egypt 1 3%
Unknown 39 98%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 9 23%
Student > Master 6 15%
Researcher 6 15%
Student > Bachelor 4 10%
Student > Postgraduate 3 8%
Other 5 13%
Unknown 7 18%
Readers by discipline Count As %
Medicine and Dentistry 13 33%
Agricultural and Biological Sciences 4 10%
Pharmacology, Toxicology and Pharmaceutical Science 3 8%
Biochemistry, Genetics and Molecular Biology 3 8%
Nursing and Health Professions 2 5%
Other 7 18%
Unknown 8 20%
Attention Score in Context

Attention Score in Context

This research output has an Altmetric Attention Score of 2. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 December 2015.
All research outputs
#15,874,665
of 25,576,275 outputs
Outputs from Clinical Interventions in Aging
#1,052
of 1,973 outputs
Outputs of similar age
#210,901
of 396,551 outputs
Outputs of similar age from Clinical Interventions in Aging
#18
of 33 outputs
Altmetric has tracked 25,576,275 research outputs across all sources so far. This one is in the 36th percentile – i.e., 36% of other outputs scored the same or lower than it.
So far Altmetric has tracked 1,973 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 11.2. This one is in the 44th percentile – i.e., 44% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 396,551 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 45th percentile – i.e., 45% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 33 others from the same source and published within six weeks on either side of this one. This one is in the 39th percentile – i.e., 39% of its contemporaries scored the same or lower than it.